基本信息 药品名称 AL002 药品类别 创新药; 生物; 抗体 靶点 triggering receptor expressed on myeloid cells 2 (TREM2) 作用机制 anti-TREM2单抗 药品简介 -- 研发机构 Alector ;AbbVie 无权益 最高研发阶段 全球: II期临床 中国: 临床前 审评审批类型 -- 外置链接 -- 了解药物更多情报 登录...
Alector(ALEC)1.40+0.72% 一位華爾街分析師今天重新審視了醫療保健行業公司Alector(ALEC -研究報告)。摩根Sta的分析師Jeffrey Hung.
2 Phase 2 trial marks a significant milestone in the ongoing development of AL002, bringing us one step closer to potentially introducing this prospective new class of therapeutics to individuals impacted by Alzheimer's disease,” said Arnon Rosenthal, Ph.D., Chief Executive Officer ...
Rychkova, AnnaAlector, Inc., South San Francisco, USARhinn, HerveLeal Therapeutics, Worcester, USATassi, IlariaDeep Apple Therapeutics, Inc., San Francisco, USAWard, MichaelIndependent Consultant, San Francisco, USABioMed CentralAlzheimer's Research & Therapy...
Custom cynomolgus monkey TREM2 MSD-based assays were developed to measure TREM2 expression in tissue or sTREM2 in CSF. Briefly, single spot MSD plates (Meso Scale Diagnostics, Rockville, MD) were coated with capture antibody 8F11 (generated at Alector) in PBS at 4oC overnight. Monkey CSF ...